{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033947","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2024-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.820637+00:00","generated_at":"2026-06-04T11:58:16.740257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vera Therapeutics FY23 net loss $96.0M; raises $287.5M; Phase 3 on track","bullets":["FY 2023 net loss $96.0M ($2.25 diluted EPS) vs $89.1M ($3.35) prior year; no revenue.","Cash $160.7M at Dec 31, 2023; subsequent $287.5M gross from Feb 2024 offering.","Phase 2b 72-week data: sustained reductions in Gd-IgA1, hematuria, UPCR with stable eGFR; Phase 3 topline 1H 2025.","Appointed Robert M. Brenner, M.D. as CMO and William D. Turner as CDO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033947","json":"https://secwatch.observer/filing/0000950170-24-033947.json","markdown":"https://secwatch.observer/filing/0000950170-24-033947.md","text":"https://secwatch.observer/filing/0000950170-24-033947.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/0000950170-24-033947-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/vera-20240320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:58:16.740257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4ccf4c8c7ee059c14bb0ecf3165bcb3d1aae64e2","claim":"Vera Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income a net loss of $96.0 million, or a net loss per diluted share of $2.25, EPS net loss per diluted share of $2.25.","evidence_excerpt":"For the year ended December 31, 2023, the company reported a net loss of $96.0 million, or a net loss per diluted share of $2.25","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000095017024033947/0000950170-24-033947-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"a net loss of $96.0 million, or a net loss per diluted share of $2.25"},{"label":"EPS","value":"net loss per diluted share of $2.25"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}